Those suffering from chronic obstructive pulmonary disease (COPD) can now seek substitute therapy to diminish their lung inflammation. As per a recent study, stem cell therapy might possibly aid in overhauling lung damage in patients with cystic fibrosis and COPD. Professionals at Queens University Belfast, UK investigated the efficiency of Mesenchymal stem cell (MSC) therapy in a mouse model of chronic inflammatory lung disease. Chronic inflammation in disorders such as COPD and cystic fibrosis results in inflammation, lung impairment and reduced lung function which might often lead to respiratory failure.

Stem cells were intravenously administered to mice at four and six weeks of age. Trial tissue and cells were then gathered from their lungs at about eight weeks. Consequently, it was found that the inflammation was considerably reduced in the group getting MSC therapy as equated to the group of mice that didn’t get the therapy. Cell count for both monocytic cells and neutrophils – signs of inflammation – were considerably reduced after MSC therapy, researchers said.On inspecting the lung tissue, it was publicized that the mean linear interrupt and other measures of lung destruction had reduced in MSC treated mice. MSC therapy also led to substantial improvements in lung structure, proposing that this form of treatment has the potential to repair impaired lung.

Highlights

Stem cell therapy might potentially aid in overhauling lung damage. It can help patients suffering from chronic obstructive pulmonary disease. MSC or stem cell therapy can help overhaul lung damage. Those suffering from chronic obstructive pulmonary disease (COPD) can now seek substitute therapy to diminish their lung inflammation. As per a recent study, stem cell therapy might potentially aid in restoring lung damage in patients with cystic fibrosis and COPD. Specialists at Queens University Belfast, UK probed the efficiency of Mesenchymal stem cell (MSC) therapy in a mouse model of chronic inflammatory lung disease. Chronic inflammation in disorders such as COPD and cystic fibrosis leads to inflammation, lung impairment and reduced lung function which might often lead to respiratory failure.Stem cells were intravenously administered to mice at four and six weeks of age. Sample tissue and cells were then gathered from their lungs at about eight weeks. Consequently, it was found that the inflammation was considerably reduced in the group getting MSC therapy as equated to the group of mice that didn’t get the therapy. Cell count for both monocytic cells and neutrophils – signs of inflammation – were considerably reduced after MSC therapy, researchers said.On examining the lung tissue, it was discovered that the mean linear intercept and other measures of lung devastation had reduced in MSC treated mice. MSC therapy also resulted in noteworthy improvements in lung structure, telling that this form of treatment has the prospective to repair damaged lung.

“These primary findings validate the potential effectiveness of MSC treatment as a means of restoring the mutilation instigated by chronic lung diseases such as COPD,” said Declan Doherty, Queens University Belfast.”The aptitude to counteract inflammation in the lungs by using the combined anti-inflammatory and reparative properties of MSCs could possibly lessen the inflammatory response in folks with chronic lung disease whilst also refurbishing lung function in these patients,” Doherty added.MSC therapy is presently being examined as a promising therapeutic methodology for a number of irredeemable, degenerative lung diseases.